tirzepatide chronic kidney disease trial Not currently a therapy. But this exploratory finding is worth watching closely. 🫘 #ObesityMedicine #Tirzepatide #Type2Diabetes #KidneyHealth #ChronicKidneyDisease #GLP1 #GIP #CardiometabolicHealth #Nephrology #MetabolicHealth #CKD #T2DM Tirzepatide and Cardiovascular Outcomes: A

Clinical studies have revealed that semaglutide GLP-1 can result in substantial weight loss, with some participants experiencing an average reduction of 15% or more of their initial body weight

Type 2 diabetes and risk of hospital admission or death for chronic liver diseases

Safety Profile and Medical Considerations GLP-1 medications are prescription-strength pharmaceutical agents

Limitations and what we do not know Both STEP 1 and SURMOUNT-1 excluded patients with diabetes, so the weight loss data apply specifically to adults with obesity but normal glucose metabolism

Other examples of sulfonamide antimicrobials: Examples of non-antimicrobial sulfonamides: Many adverse reactions to sulfonamides are not of an allergic nature

For example, Butyrate-producing bacteria might be beneficial in ALS (butyrate has neuroprotective properties, as described) [216]